Li, Bob T. http://orcid.org/0000-0001-6661-8733
Daly, Bobby
Gospodarowicz, Mary
Bertagnolli, Monica M.
Brawley, Otis W.
Chabner, Bruce A.
Fashoyin-Aje, Lola
de Claro, R. Angelo
Franklin, Elizabeth
Mills, Jennifer
Legos, Jeff
Kaucic, Karen
Li, Mark
The, Lydia
Hou, Tina
Wu, Ting-Hui
Albrecht, Bjorn
Shao, Yi
Finnegan, Justin
Qian, Jing
Shahidi, Javad
Gasal, Eduard
Tendler, Craig
Kim, Geoffrey
Yan, James
Morrow, Phuong Khanh
Fuchs, Charles S.
Zhang, Lianshan
LaCaze, Robert
Oelrich, Stefan
Murphy, Martin J.
Pazdur, Richard
Rudd, Kevin
Wu, Yi-Long http://orcid.org/0000-0002-3611-0258
Article History
First Online: 19 April 2022
Competing interests
: The authors have not received any financial compensation for this publication. Outside this submitted work, B.T.L. has served as an uncompensated advisor and consultant to Amgen, Genentech, Boehringer Ingelheim, Lilly, AstraZeneca, Daiichi Sankyo, has received research grants to his institution from Amgen, Genentech, AstraZeneca, Daiichi Sankyo, Lilly, Hengrui USA, MORE Health and Bolt Biotherapeutics and has received academic travel support from MORE Health and Jiangsu Hengrui Medicine. He is an inventor on two institutional patents at Memorial Sloan Kettering Cancer Center (US62/685,057, US62/514,661) and has intellectual property rights as a book author at Karger Publishers and Shanghai Jiao Tong University Press. B.D. owns stock in Roche and served on the advisory board of Varian Medical Systems. M.M.B. has served on the Board of Directors of American Cancer Society, Prevent Cancer Foundation, Natera, Inc., Leap Therapeutics and Oncoclinicas do Brasil Servicos Medicos, and has received institutional research funding to the Alliance for Clinical Trials in Oncology Foundation from AbbVie, Agenus, Astellas, AstraZeneca, Baxalta, Bayer HealthCare, the Breast Cancer Research Foundation, Bristol-Myers Squib, Celgene, Complion, Czarnowski, Derse, Inc., Eisai, Exelixis, Flame Biosciences, Genentech, GHI, Gilead Sciences, GSK Total, Incyte Corporation, Janssen, Jazz Pharma, Leap Therapeutics, Leidos, Lexicon Pharma, Lilly, Maltrex, Merck, Millennium, MITRE Corporation, Novartis, Pfizer, Pharmacyclics, the Robert Wood Johnson Foundation, Roche/Genentech, Sagerock Advisors, Sanofi, the Society for Translational Oncology, Taiho Oncology, Takeda, Tesaro and Teva. J.M. is an employee of Foundation Medicine, Inc. and owns stock in Roche, Merck, Abbott and Abbvie. M.L. is an employee and shareholder of Agilent Technologies, Inc. J.L. is an employee and shareholder of Novartis. K.K. is an employee of PPD Inc. L.T., T.H., B.A. and Y.S. are employees of McKinsey & Company. T.-H.W. is a former employee of McKinsey & Company and current employee of Omega Therapeutics. J.F. is an employee of Bloomberg L.P. J.S. is an employee of Daiichi Sankyo. E.G. is an employee and shareholder of Innovent Biologics. C.T. is an employee and shareholder of Janssen, Johnson and Johnson. J.Y. is an employee and shareholder of Zai Lab. P.K.M. is an employee and shareholder of Amgen. C.S.F. is an employee and shareholder of Genentech and Roche. L.Z. is an employee and shareholder of Jiangsu Hengrui Pharmaceuticals. R.L. and S.O. are employees and shareholders of Bayer. The other authors declare no competing interests.
Free to read: This content has been made available to all.